Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Madrigal's Rezdiffra improves or stabilizes liver stiffness in up to 93% of patients in real-world studies

By Public Technologies
  • Madrigal Pharmaceuticals announced real-world Rezdiffra results presented at AASLD’s 2026 Liver Meeting for metabolic dysfunction-associated steatohepatitis.
  • Most patients showed improved or stable liver stiffness roughly one year into treatment, with additional improvements in liver fat and cardiometabolic markers.
  • Benefits were observed regardless of concurrent GLP-1 therapy, supporting use across patients with common metabolic conditions.
  • Most patients remained on treatment at one year, with high adherence among those continuing therapy.
  • Safety findings were consistent with clinical trials; reported treatment-related adverse events were infrequent.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Madrigal Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611051000PRIMZONEFULLFEED9870944) on November 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.